Regulation of estrogen receptor (ER) function in breast cancer cells is a complex process involving different signalling mechanisms. One signal transduction component that appears to influence ER signalling is protein kinase C (PKC). PKCd is a particular isoenzyme of the novel PKC subfamily that plays a role in growth control, differentiation and apoptosis. The aim of the present study was to investigate the impact of PKCd on the regulation of the transcriptional activity of the human ERa. By using 12-O-tetradecanoylphorbol-13-acetate (TPA), Bryostatin1 and Rottlerin, we show that active PKCd is a proproliferative factor in estrogen-dependent breast cancer cells. Furthermore, activation of PKCd by TPA resulted in activation and nuclear translocation of ERa and in an increase of ER-dependent reporter gene expression. Transfection and expression of the regulatory domain RDd of PKCd, which is inhibitory to PKCd, inhibited the TPA-induced ERa activation and translocation. ERa was not phosphorylated by PKCd; however, glycogen synthase kinase-3 (GSK3) was identified as a substrate of PKCd. The expression of RDd resulted in a decrease of TPA-induced GSK3 phosphorylation and translocation into the nucleus. We suggest that GSK3 plays a role in the PKCd-related nuclear translocation of ERa.
Introduction
The estrogen receptor (ER) is a member of the superfamily of nuclear hormone receptors that function as transcription factors Beato et al., 1995) . The two ER isoforms, ERa and ERb, differ in tissue distribution, ligand specificity and physiological function (Matthews and Gustafsson, 2003) , ERa being the predominant isoform in breast cancer cells (Hall et al., 2001) . ERa consists of three structural domains, a variable N-terminal domain, a highly conserved DNAbinding domain and a moderately conserved C-terminal ligand-binding domain. ERs are located predominantly in the cell nucleus, but undergo a process of nucleocytoplasmic shuttling . The classical model of ERa transcriptional activation involves ligand binding, formation of homodimers, nuclear translocation, binding of the receptor to specific DNA sequences, the estrogen response elements (ERE) located within the regulatory regions of target genes and induction of gene transcription (Kumar and Chambon, 1988; Fawell et al., 1990) . Transcriptional activity of ERa is mediated by two activation domains, a hormone-independent activation function-1 (AF-1) located within the N-terminus, and a hormone-dependent AF-2 in the ligand-binding domain. ERa is a phosphoprotein, phosphorylation at serine 118 (Ser118) located in the AF-1 domain is required for receptor dimerization, DNA binding and full transcriptional activation (Migliaccio et al., 1986; Le Goff et al., 1994; Lannigan, 2003) .
Although ERa activity is controlled mainly by estrogen, it is now well established that ERa-mediated transcription can also be stimulated by ligand-independent mechanisms involving second messenger signalling pathways (Ignar-Trowbridge et al., 1992; Bunone et al., 1996) . One signal transduction component that appears to influence ERa activity is protein kinase C (PKC) (Borner et al., 1987; Cho and Katzenellenbogen, 1993) .
The PKC family comprises at least 11 isoforms, which comprise three subfamilies, the classical, novel and atypical PKCs. These differ in tissue distribution, requirements for activation and substrate specificities (Toker, 1998) , and seem to have unique roles in signal transduction (Dempsey et al., 2000) . Upon stimulation of phospholipase-C-linked receptors, PKC is catalytically activated by diacylglycerol (DAG) and translocates from soluble to membrane compartments of the cells. This translocation is also achieved by treatment with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) that mimics the structure of DAG and binds to PKC (Kraft et al., 1982) . PKC isoforms control a large number of cellular functions through specific phosphorylation of intracellular substrates including steroid receptors (Cho and Katzenellenbogen, 1993) . Alterations in PKC activity modulate ERa responsiveness of different cell lines in vitro and may result in the loss of estrogen responsiveness in breast cancer. An inverse relationship exists between the level and activity of PKCs and the level of ERa in human mammary carcinoma cells (Borner et al., 1987) . Furthermore, activation of PKC by phorbol esters downregulates ERa in estrogen-dependent MCF-7 breast cancer cells (Ree et al., 1991; Tzukerman et al., 1991) . PKCa has been attributed a particular role in ERa function in T47D cells (Tonetti et al., 2000) , osteoblasts (Longo et al., 2004) and HepG2 cells (Marino et al., 2001) .
In this study, we focused on PKCd, a member of the novel PKC subfamily that is involved in growth control, differentiation and apoptosis (Kikkawa et al., 2002) , and represents the predominant isoform in MCF-7 cells (Shanmugam et al., 1999) . Reports on PKCd function in estrogen-responsive tissues are contradictory. PKCd was upregulated by estradiol in corpus luteum (Maizels et al., 1996) , while it was downregulated in MCF-7 cells in a time-and dose-dependent manner (Shanmugam et al., 1999) . PKCd increased mammary tumour cell growth and metastasis by activation of the Ras/Erk1/2 pathway (Keshamouni et al., 2002) . The activity of murine ERa was stimulated by PKCd and the effect required phosphorylation of serine 122 in the AF-1 region (Lahooti et al., 1998) . Based on these observations and because multiple feedback pathways appear to link PKCd and ERa signalling, it was conclusive to investigate the specific role of PKCd in human estrogendependent cells. The aim of our study was to elucidate the potential interaction of PKCd with ERa expression and activity in breast cancer cells. By expression of the regulatory domain RDd of PKCd, which inhibits PKCd selectively (Kiley et al., 1999a) and by use of the PKCd inhibitor Rottlerin (Gschwendt et al., 1994) , we studied the function of PKCd and of TPA-induced effects on intracellular localization and activity of ERa. RDd contains the autoinhibitory pseudosubstrate motif that interferes with endogenous PKCd by directly inhibiting the catalytic activity. In addition, RDd may interact with binding proteins that target PKCd to assigned subcellular locations (Mochly-Rosen and Gordon, 1998) .
Results

Effects of estradiol and TPA on PKCd and ERa content in MELN cells
Long-term treatment of MELN cells with estradiol (E2) resulted in a decrease in ERa protein (Figure 1a ), which agrees with previous reports (Reid et al., 2003) . In addition, E2 treatment resulted in a marked decrease of PKCd protein, downregulation being clearly visible after 24 h of treatment. The specificity of the E2 effect was shown using the estrogen antagonist ICI 182 780, which blocked E2-induced downregulation of PKCd (Figure 1b) . Treatment of the cells with TPA, an activator of PKC, resulted not only in downregulation of PKCd (Figure 1c ), a finding described previously for other PKC isoforms in different systems (Liu and Heckman, 1998) , but also of ERa with similar kinetics. 
Effects of PKCd activation or inhibition on MELN cell growth
We examined the effects of different PKCd activators and inhibitors on the growth of MELN cells: TPA, a PKC activator that after long-term treatment leads to PKC downregulation, Rottlerin, a selective PKCd inhibitor, and Bryostatin1, an activator of PKC that in long-term treatment protects only PKCd from TPAinduced downregulation (Lorenzo et al., 1999) . Cell counts obtained during a 72 h treatment with these compounds are shown in Figure 1d . Estradiol treatment was used as a control to stimulate proliferation. TPA treatment resulted in a marked decrease in cell number in comparison with both E2-treated and -untreated cells. Bryostatin1 in combination with TPA completely antagonized TPA-induced growth inhibition. Rottlerin alone or in combination with TPA led to a complete inhibition of growth. These findings suggest that PKCd in its active state is a proproliferative (prosurvival) factor in MELN cells.
Cloning of expression constructs of full-length PKCd and RDd and expression of the proteins
We generated expression constructs carrying the fulllength sequence of PKCd (amino acids 1-676) or RDd (amino acids 1-299 of PKCd) (Figure 2a) , both followed by a double FLAG-tag sequence that permitted detection of the proteins in Western blots (Figure 2b) .
In MELN cells transiently transfected with the RDd expression construct, RDd was localized to the membrane fraction (Figure 2c ). In these cells, endogenous PKCd was equally distributed between cytosolic and particulate fractions, while in mock-transfected cells, endogenous PKCd was localized predominantly to the particulate fraction. Thus, RDd expression inhibited PKCd localization to membranes, a process that is required for full activation of PKCd. Further, a strong increase in the amount of the catalytic fragment of PKCd was observed in RDd-transfected cells (Figure 2c ), suggesting a reduced stability of endogenous PKCd after RDd expression. The overexpressed fulllength PKCd protein was accumulated in the cytosol of nontreated cells. TPA treatment caused a translocation of both endogenous and transfected PKCd to membranes (particulate fraction) (Figure 2d ).
Influence of PKCd activators and inhibitors on EREcontrolled gene expression
The influence of PKCd on ERa-regulated gene expression was investigated by performing luciferase assays in MELN cells using different activators and inhibitors of PKCd. E2 treatment served as control for activation of ERa and induction of ERE-controlled luciferase (Figure 3a) . TPA stimulation resulted in 1.7-fold induction of luciferase activity that was further increased by simultaneous treatment with Bryostatin1. Treatment with Rottlerin inhibited basal and TPA-induced as well as TPA/Bryostatin1-induced luciferase expression. We conclude that TPA stimulates transcriptional activity of ERa via PKCd, and that PKCd in its active state is required for ERa activation in MELN cells. The involvement of PKCd in ERaregulated gene expression was confirmed by luciferase assays in cells transfected with RDd, where both basal and TPA-induced luciferase activity were found to be decreased ( Figure 3b ).
Phosphorylation of ERa
The effects of PKCd on ERa activation and function were further analysed by investigating ERa phosphorylation on Ser118. We transfected cells with RDd and full-length PKCd, respectively, treated the cells with TPA and analysed Ser118 phosphorylation using a specific antibody. Phosphorylation was slightly increased after TPA treatment in comparison with untreated cells, but there were no visible differences in signal intensity among mock-transfected, full-length PKCd and RDd-transfected cells (Figure 4a ). Rottlerin treatment did also not result in inhibition of TPAinduced ERa phosphorylation (Figure 4b ). We concluded that ERa was not phosphorylated by PKCd. This Cell lysates were subjected to Western blot analysis. Immunodetection was performed using an antibody that recognizes specifically ERa phosphorylated on Ser118. The same membrane was probed with anti-ERa to detect the ERa-protein. C, control for the detection of ERa phosphorylation (MELN cells stimulated for 20 min with 100 nM estradiol and 100 ng/ml EGF). (b) MELN cells were treated with 50 nM TPA alone or in combination with 5 mM Rottlerin. ERa protein and ERa phosphorylated on Ser118 were detected by immunoblotting. (c) In vitro phosphorylation assay. FLAG-tagged PKCd was overexpressed in MELN cells and immunoprecipitated with anti-FLAG. The precipitate was incubated with rhERa (1 mg) and TPA/PS (1 mM/ 50 mg/ml) as activators of PKCd. Phosphorylation of ERa was analysed by immunoblotting with anti-pSer118 and anti-ERa. (d) Cells were transfected with empty vector (mock) or RDd and treated with 50 nM TPA for 20 min. Soluble (s), particulate (p) and nuclear (n) fractions were obtained by differential centrifugation. The proteins of the fractions were submitted to Western blot analysis using anti-pSer118 and anti-ERa antibodies. (e) Cells were treated for 10 min with Rottlerin (5 mM) or the vehicle (mock) before the addition of TPA (50 nM, 20 min). Soluble (s), particulate (p) and nuclear (n) fractions were analysed by Western blotting using the same antibodies as in (d) PKCd interaction with estrogen receptor B De Servi et al was confirmed in an in vitro phosphorylation assay using FLAG-tagged PKCd immunoprecipitated from the lysate of transfected cells and recombinant human ERa (rhERa) as substrate. The addition of TPA and the coactivator phosphatidylserine (PS) did not lead to increased ERa phosphorylation (Figure 4c ).
Effect of RDd expression on intracellular localization of ERa
Mock-and RDd-transfected cells were treated with TPA and the cell homogenates were fractionated into soluble, particulate and nuclear fractions. TPA treatment resulted in ERa translocation into the nuclear fraction of mock-transfected cells, this effect was clearly decreased in the RDd-transfected cells (Figure 4d) . Analysis of Ser118 phosphorylation of ERa on the same membrane revealed a TPA-induced phosphorylation that was similar in mock-or RDd-transfected cells. Rottlerin did not show an inhibitory effect on TPAinduced ERa phosphorylation and translocation. Prolonged preincubation times with Rottlerin (up to 12 h) before the addition of TPA yielded similar results (not shown).
Implication of glycogen synthase kinase-3 (GSK3) in PKCd-dependent signalling to ERa
Since activation of PKCd resulted in translocation and activation of ERa, but ERa was not a substrate of PKCd, we wondered how TPA-induced translocation of ERa was regulated. The activation of classical PKC resulted in phosphorylation of GSK3 (Frame and Cohen, 2001; Jope and Johnson, 2004) . We therefore hypothesized that GSK3 may be a link between PKCd and ERa. GSK3 was shown to represent a substrate of PKCd by using immunoprecipitated FLAG-tagged PKCd and GSK3 fusion protein as substrate in an in vitro phosphorylation assay with or without the activation of PKCd by TPA/PS (Figure 5a ). Active PKCd clearly phosphorylated GSK3.
To further analyse the role of GSK3 in PKCd signalling to ERa, we studied the effect of RDd expression on localization and phosphorylation of GSK3. RDd-or mock-transfected MELN cells were treated with TPA, homogenized and fractionated, and the phosphorylation state and intracellular localization of GSK3 were analysed (Figure 5b ). Basal phosphorylation of GSK3a/b was decreased in RDdtransfected cells in all fractions. GSK3a/b phosphorylation was slightly increased by TPA treatment in mock-transfected cells, but not in RDd-transfected cells. Further, we observed a nuclear translocation of GSK3 in mock-transfected cells induced by TPA, which was less pronounced in RDd-transfected cells. We concluded that inhibition of PKCd activity by its regulatory pseudosubstrate results in reduced phosphorylation and translocation of GSK3 into the nucleus. Rottlerin studied for comparison yielded similar results (Figure 5c ).
Detection of intracellular ERa and GSK3 localization by immunofluorescence microscopy
The translocation of ERa and GSK3 into the nucleus under the influence of TPA and inhibition of the translocation by overexpression of RDd was confirmed by immunofluorescence microscopy. In mock-transfected untreated MELN cells, signals for ERa and GSK3 proteins were detected in both the cytoplasm and the nuclei (Figure 6a and e) . After TPA treatment, a strong fluorescence staining of ERa and GSK3 proteins occurred in the nuclei (Figure 6c and g ). In contrast, in cells transfected with the RDd construct and treated with TPA, the nuclear staining of both proteins was significantly reduced (Figure 6d and h) and similar to controls (Figure 6b and f) .
Discussion
Knowledge of the interactions between signalling pathways and ERa activity is of great importance since it may provide information on potential targets for The clarification of the functional interaction between PKCd and ERa is of particular interest, since the precise role of PKCd in cell survival in estrogen-dependent breast cancer cells is still unclear (McCracken et al., 2003) . In the present study, we show that PKCd is involved in estradiol-independent TPA-induced activation of the ERa. A first hint on the interaction between PKCd and ERa came from the downregulation of both proteins observed after treatment of ERa-positive breast cancer cells with TPA and estradiol, which was in line with reports on the downregulation of PKCd by TPA and estrogen (Gschwendt, 1999; Shanmugam et al., 1999) . Other authors reported that long-term treatment of MCF-7 cells with TPA resulted in a block of ERa activity (Martin et al., 1995) or a decrease of ERa protein, ERa mRNA and DNA binding capacity (Saceda et al., 1991) . These findings suggested a crosstalk between PKCd and ERa functions, and we hypothesized that PKCd signalling may be related to ERa activation.
MCF-7 cells have been reported to be highly sensitive to growth inhibition by phorbol esters (Valette et al., 1987) , which agrees with our results. Since PKCd is the predominant PKC isoform in MCF-7 cells (Shanmugam et al., 1999) , this growth inhibition may be related to PKCd signalling. The observation that Bryostatin1 completely antagonized the growth inhibition induced by TPA suggests that PKCd in its active state supports cell growth. These findings also suggest that growth retardation induced by TPA is due to degradation of PKCd after prolonged exposure to TPA. The observation that Rottlerin alone or in combination with TPA led to a complete inhibition of growth also supports the conclusion that PKCd is a proproliferative or prosurvival factor in MELN cells. A role for active PKCd in promoting mammary tumour cell growth has been previously suggested by Keshamouni et al. (2002) , who described that cell growth induced by PKCd activation was inhibited by Rottlerin or a dominant-negative mutant of PKCd. In addition, the expression of the inhibitory PKCd regulatory domain inhibited growth in soft agar, cell motility and attachment in MTLn3 mammary tumour cells (Kiley et al., 1999b) .
The positive correlation between PKCd activity and proliferation of estrogen-dependent breast cancer cells prompted us to investigate if PKCd activation influenced the activity of ERa. Using a reporter gene assay in which ERa activation was evaluated by induction of ERE-controlled luciferase, we could show that activation of PKCd by TPA and Bryostatin1 indeed resulted in ERa activation. Together with the finding that ERa activation was completely inhibited by Rottlerin and by expression of RDd, these data suggest that TPA stimulates the ERE-dependent transcriptional activity of ERa via activation of PKCd. The data agree with findings from another study where activation of PKCd (Lahooti et al., 1998) .
The activation of the ERa by its physiological ligand estradiol is accompanied by phosphorylation of Ser118 located in the AF-1 domain of the receptor, which is required for full activation of ERa (Lannigan, 2003) . Interestingly, TPA treatment also resulted in Ser118 phosphorylation. This may be interpreted as a ligandindependent phosphorylation/activation of ERa. Our data are in line with results from Le Goff et al. (1994) and Joel et al. (1995) , who showed that TPA caused phosphorylation of Ser118 of the human ER expressed in Cos-1 cells. However, TPA-induced ERa phosphorylation was not due to PKCd as it was not inhibited by RDd expression or Rottlerin treatment. The protein kinase that phosphorylates ERa in TPA-treated cells remains to be identified.
Another criterion that is crucial for the transcriptional activation of ERa is its nuclear translocation (Hall et al., 2001) . TPA treatment clearly resulted in nuclear translocation of ERa documented by cell fractionation experiments and immunofluorescence microscopy. Overexpression of RDd markedly inhibited TPA-induced nuclear accumulation of ERa, confirming a function of PKCd in ERa activation. Unexpectedly, Rottlerin showed no clear inhibitory effect on ERa translocation; however, Rottlerin is a less specific inhibitor of PKCd than RDd and may exert unknown effects on cell functions.
The findings discussed so far suggest that PKCd triggers an unknown signalling pathway that leads to ERa activation by phosphorylation and nuclear translocation. Co-immunoprecipitation experiments excluded a direct interaction of PKCd and ERa in unstimulated or TPA-stimulated cells (data not shown). An enzyme that is involved in transduction of TPA-induced PKC effects (Frame and Cohen, 2001 ) and that plays a role in the regulation of ERa signalling is the GSK3 (S Medunjanin et al., unpublished data). GSK3 is a key component of a large number of cellular processes, its activity is reduced by phosphorylation at a serine residue in the N-terminus. Protein kinases that phosphorylate/inactivate GSK3 are, for example, PKB/Akt, protein kinase A and classical PKC (Grimes and Jope, 2001). Two isoforms of GSK3 (GSK3a/b) have been described, but little is known about isoform-specific functions (Jope and Johnson, 2004) .
GSK3 has been reported as a substrate of classical PKC (Jope and Johnson, 2004) and of fragmented PKCd generated during the process of apoptosis in human neuroblastoma cells (Tsujio et al., 2000) . We could show by in vitro kinase assays that GSK3 is a potential substrate for PKCd. In vivo analysis of the implication of GSK3 in PKCd-dependent signalling to ERa showed that TPA treatment caused phosphorylation of GSK3 and partial nuclear translocation. Interestingly, we observed a reduction in basal and TPAinduced phosphorylation of GSK3a/b in RDd-transfected cells, suggesting that GSK3 is a substrate for PKCd in vivo. The meaning of the observed difference in phosphorylation patterns of GSK3a and GSK3b remains to be elucidated. In addition, RDd expression and Rottlerin prevented nuclear translocation of GSK3 observed after TPA treatment in controls. The data suggest that GSK3 phosphorylation by PKCd triggers translocation of GSK3 into the nucleus. TPA-related nuclear GSK3 translocation coincided with ERa translocation described above. In line with these findings, we observed a shift from cytoplasmic to nuclear staining of both GSK3 and ERa proteins in TPA-treated cells in immunofluorescence experiments, which was not detected in cells transfected with RDd.
From the results presented, we suggest the following model (Figure 7) . In unstimulated cells GSK3 forms a complex with ERa in the cytoplasm (S Medunjanin et al., unpublished data). After TPA treatment, PKCd is active and phosphorylates GSK3. Phosphorylated GSK3 and ERa translocate into the nucleus. RDd overexpression results in the inhibition of PKCd and Figure 7 Model for PKCd involvement in TPA-induced activation of ERa. (a) In unstimulated cells, PKCd is localized to the cytoplasm. After TPA treatment active PKCd translocates to the membrane fraction and phosphorylates GSK3. GSK3, which in unstimulated cells is active and forms a complex with ERa, is inactivated by phosphorylation. The phosphorylation of GSK3 may trigger the nuclear translocation of both ERa and GSK3 proteins. ERa is activated by phosphorylation in the nucleus. (b) In RDd-transfected cells, PKCd is inhibited. As a consequence, phosphorylation of GSK3 is reduced. Under these conditions, GSK3 is active and like in unstimulated cells binds to ERa, thereby preventing its nuclear translocation PKCd interaction with estrogen receptor B De Servi et al decreased phosphorylation of GSK3. Under these conditions, GSK3 is active and, like in unstimulated cells, complexes with ERa probably trapping it in the cytoplasmic compartment and preventing its nuclear translocation. In conclusion our data suggest an impact of PKCd on the intracellular localization and activity of ERa, stimulating nuclear translocation of ERa.
Materials and methods
Materials
MELN cells were derived from MCF-7 cells by stable transfection with a plasmid carrying the firefly luciferase gene under the control of the estrogen response element (ERE-luc) using the b-globin promoter (Le Bail et al., 1998) . 17b-estradiol, TPA, PS and protein A-agarose were from Sigma (Mu¨nchen, Germany), ICI 182 780 from Tocris (UK), Rottlerin from Calbiochem (San Diego, CA, USA), Bryostatin1 from Biomol (Hamburg, Germany) and a protease inhibitor cocktail (EDTA-free) from Roche (Mannheim, Germany). The luciferase assay system was from Promega (Mannheim, Germany). Tissue culture media and reagents were from Invitrogen (Karlsruhe, Germany) and Biochrom (Berlin, Germany). PVDF membranes (Immobilon P) for Western blots were from Millipore (Eschwege, Germany). The ECLplus system was from Amersham Biosciences (Freiburg, Germany). Protein markers and the DC protein assay kit were from BioRad (Mu¨nchen, Germany). rhERa was from Panvera (Madison, WI, USA) and GSK3 fusion protein from Cell Signalling Technology (New England Biolabs, Frankfurt/ Main, Germany). The following antibodies were used: goat anti-PKCd (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-FLAG (Sigma), mouse anti-ERa (Novocastra, Newcastle, UK and Santa Cruz), mouse antiphosphoSer118-ERa and rabbit antiphospho-GSK3a/b and GSK3b (Cell Signalling Technology), mouse antitubulin (Upstate, Lake Placid, NY, USA). Peroxidase-labelled secondary antibodies were from Dianova (Hamburg, Germany). Cy3-conjugated anti-rabbit antibody and Alexa 488 anti-mouse antibody were from Jackson Immunoresearch (West Grove, PA, USA).
Cell culture
Cells were maintained in phenol red-free DMEM/10% FCS (fetal calf serum). For experiments, 2 Â 10 6 cells/dish were grown in DMEM/10% DCC-FCS (stripped with dextrancoated charcoal according to Migliaccio et al., 1993) . After 48 h in estrogen-depleted medium, the cells were incubated overnight with DMEM containing 1% DCC-FCS, then TPA (50 nM), Bryostatin1 (1 mM), Rottlerin (5 mM) or estradiol (10 nM) were added. After washing with phosphate-buffered saline (PBS), the cells were scraped at time points indicated.
Lysis of cells
For total cell lysate preparation, cell pellets were suspended in ice-cold lysis buffer (1.5% Triton X-100, 50 mM HEPES (pH 7.6), 150 mM NaCl, 1.5 mM MgCl 2 , 10% glycerol, 10 mM Na 4 P 2 O 7 Â 10 H 2 O, 5 mM EDTA, protease inhibitors, 4.2 mg/ml Na fluoride, 0.5 mg/ml Na orthovanadate) and incubated on ice for 30 min. The lysate was centrifuged at 15 000 g at 41C for 10 min and the protein content was determined.
Preparation of cytosol and membrane extracts
Cells were homogenized in buffer A (protease and phosphatase inhibitors, 2 mM Tris-HCl (pH 7.5), 2 mM EDTA, 0.5 mM EGTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF) using a glass potter. Nuclei were removed by centrifugation at 800 g for 5 min. The 800 g supernatant was centrifuged at 100 000 g for 20 min at 41C and the supernatant (cytosol) was collected. Triton X-100 solubilized membrane fractions were prepared by resuspending the 100 000 g pellet in buffer A containing 1% Triton X-100 followed by sonication. The supernatant obtained after centrifugation at 15 000 g constituted the Triton X-100-solubilized membrane fraction. Aliquots were denatured by the addition of 2 Â SDS sample buffer (2% SDS, 150 mM Tris-HCl (pH 6.8), 2.4 mM EDTA, 3% b-mercaptoethanol, 30% glycerol and 0.5% bromophenol blue) and boiling for 5 min.
Preparation of nuclear extracts
Pelleted cells were suspended in nuclear buffer N1 (10 mM HEPES (pH 7.8), 10 mM KCl, 2 mM MgCl 2 , 0.1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, protease inhibitors, 0.6% Triton X-100) and homogenized using a glass potter. The nuclei were collected by centrifugation at 5000 g (10 min at 41C), washed in the same buffer, resuspended in 500 ml nuclear buffer N2 (50 mM HEPES (pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 10% glycerol) and incubated on ice for 10 min. After centrifugation at 15 000 g, the supernatant containing the nuclear proteins was denatured by boiling in 2 Â SDS sample buffer.
Western blot analysis
Denatured samples were subjected to SDS-polyacrylamide gel electrophoresis in electrophoresis buffer (25 mM Tris, 250 mM glycine, 0.1% SDS) (Laemmli, 1970) . Proteins were then blotted on an Immobilon-P membrane in transfer buffer (50 mM Tris-Base, 380 mM glycine, 20% methanol) for 2 h at 400 mA at 41C and detected by immunoblotting using the indicated antibodies and the ECL-plus system.
Firefly luciferase reporter gene assay
To determine ER-dependent luciferase expression MELN cells were plated in DMEM/10% DCC-FCS at a density of 1 Â 10 5 cells/well in six-well plates. After 2 days, medium was changed to DMEM containing 0.5% DCC-FCS. After further 24 h, compounds (estradiol, TPA, Bryostatin1, Rottlerin) were added at different concentrations and cells were incubated for 24 h. Then, the cells were washed twice with PBS (Mg 2 þ and Ca 2 þ free) and lysed in 150 ml/well Luciferase Cell Culture Lysis Reagent on ice for 30 min. The lysate was centrifuged, and the protein content was determined. A measure of 100 ml of the Luciferase assay reagent and 20 ml of the lysates were mixed and luminescence was determined in a luminometer (Biolumat LB6505, Berthold, Bad Wildbad, Germany). At least two independent experiments were performed under the same conditions and measured in duplicates.
Cell growth studies MELN cells were plated in DMEM/10% DCC-FCS at a density of 1 Â 10 5 cells/well in six-well plates. After 24 h, the medium was replaced by fresh DMEM containing TPA, Bryostatin1, Rottlerin or estradiol. Cells were counted after 24, 48 and 72 h.
PKCd expression vectors
The sequence coding for the regulatory domain fragment RDd of human PKCd, an 897 bp fragment encoding amino-acid residues 1-299, was amplified by RT-PCR (forward primer: 5 0 -tatagctagccaccatggcgccgttcctgcgcatc-3 0 , reverse primer: 5 0 -tataggatccggaggctctctgggtgacttggttc-3 0 ) and cloned into NheI/ BamHI restriction sites in a pcDNA3.1-derived vector containing a double FLAG-tag sequence at the 3 0 side of the polylinker.
The full-length PKCd sequence (2028 bp corresponding to amino acids 1-676) was also amplified by RT-PCR (forward primer: 5 0 -tatagctagccaccatggcgccgttcctgcgcatc-3 0 ; reverse primer: 5 0 -tataggatccatcttccaggaggtgctcgaatttgg-3 0 ) and cloned into the NheI/BamHI restriction sites of the same vector permitting expression of the FLAG-tagged protein. MELN cells were transiently transfected by electroporation (Gene Pulse, BioRad. Conditions: 975 mF, 250 V).
In vitro phosphorylation assays
MELN cells were transfected with full-length PKCd-FLAG. Cell lysates (300 mg protein) were precleared for 1 h with 25 ml protein A-agarose at 41C and subjected to immunoprecipitation overnight at 41C using 2 mg anti-FLAG. Protein A-agarose precipitates were washed 3 Â with lysis buffer and 1 Â in phosphorylation buffer (25 mM Tris (pH 7.4), 5 mM MgCl 2 , 0.5 mM EGTA, 1 mM DTT, 10 mM b-mercaptoethanol, 200 mM ATP). The immunoprecipitates were incubated at 301C for 20 min with 1 mg rhERa or 1 mg GSK3 fusion protein as substrates in phosphorylation buffer with or without PKC activators (1 mM TPA, 50 mg/ml PS). Phosphorylation of ERa and GSK3 was analysed using phospho-specific antibodies.
Immunofluorescence
Cells were transfected with the RDd expression construct and grown on poly-D-lysine-coated glass coverslips for 24 h in DMEM/10% DCC-FCS. Then, the medium was replaced by serum-free DMEM and after additional 24 h, the cells were treated with 50 nM TPA for 20 min. Cells were fixed with methanol for 5 min and with acetone for 1 min at À201C, washed with PBS and incubated with anti-ERa (1 : 50 in PBS) and anti-GSK3 antibodies (1 : 50 in PBS) for 1 h at room temperature. After washing in PBS, coverslips were incubated with Cy3-conjugated anti-rabbit antibody and Alexa 488 antimouse antibody for 1 h at room temperature and mounted in Mowiol. Fluorescence was viewed under an Axiovert S100 TV microscope at wavelengths of 490 nm (Alexa) and 550 nm (Cy3).
Abbreviations DAG, diacylglycerol; ER, estrogen receptor; ERE, estrogen response element; PKC, protein kinase C; PMSF, phenylmethylsulfonyl fluoride; PS, phosphatidylserine; RDd, regulatory domain of PKCd; TPA, 12-O-tetradecanoylphorbol-13-acetate.
